Comparison of Seroconversion in Children and Adults With Mild COVID-19

  1. Zheng Quan Toh
  2. Jeremy Anderson
  3. Nadia Mazarakis
  4. Melanie Neeland
  5. Rachel A. Higgins
  6. Karin Rautenbacher
  7. Kate Dohle
  8. Jill Nguyen
  9. Isabella Overmars
  10. Celeste Donato
  11. Sohinee Sarkar
  12. Vanessa Clifford
  13. Andrew Daley
  14. Suellen Nicholson
  15. Francesca L. Mordant
  16. Kanta Subbarao
  17. David P. Burgner
  18. Nigel Curtis
  19. Julie E. Bines
  20. Sarah McNab
  21. Andrew C. Steer
  22. Kim Mulholland
  23. Shidan Tosif
  24. Nigel W. Crawford
  25. Daniel G. Pellicci
  26. Lien Anh Ha Do
  27. Paul V. Licciardi

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1001/jamanetworkopen.2022.1313
  2. ScreenIT

    SciScore for 10.1101/2021.10.17.21265121: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: Written informed consent and assent were obtained from adults/parents and children, respectively.
    IRB: The study was done with the approval of the Human Research Ethics Committee (HREC) at the Royal Children’s Hospital, Melbourne: HREC/63666/RCHM-2019.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Goat anti-human IgG-(1:10,000) horseradish peroxidase (HRP) conjugated secondary antibody was used, and the plates were developed using 3.3’, 5.5’-tetramethylbenzidine substrate solution.
    anti-human IgG-
    suggested: (GenWay Biotech Inc. Cat# 20-783-75007-0.2 mg, RRID:AB_1023061)
    Liaison SARS-CoV-2 S1/S2 IgG assay (Saluggia, Italy): The quantitative commercial assay for the detection of IgG antibodies against S1/S2 antigens of SARS-CoV-2 was done according to the manufacturer’s instructions.
    S1/S2
    suggested: None
    Wantai SARS-CoV-2 antibody ELISA (Beijing, China): This qualitative commercial assay detects total antibodies (including IgG and IgM) to SARS-CoV-2 RBD antigen.
    IgM
    suggested: None
    SARS-CoV-2 RBD antigen.
    suggested: None
    Software and Algorithms
    SentencesResources
    Data were analysed by FlowJo (Tree Star).
    FlowJo
    suggested: (FlowJo, RRID:SCR_008520)
    All analyses were performed with GraphPad Prism 7.0.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Limitations of this study include the small sample size particularly for the cellular analyses. In addition, our study cohort of mild COVID-19 among children and adults may not be generalizable to other study populations such as older adults or individuals with underlying medical conditions. This is the first study that documents a higher proportion of children who do not seroconvert compared to adults, despite a similar clinical and virological profile. Seronegative children are at a greater potential risk of reinfection. Our findings have important implications for public health responses in controlling SARS-CoV-2 infection among children and supports COVID-19 vaccination strategies once priority groups have been vaccinated.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.10.17.21265121 on medRxiv